Endoscopic therapeutic esophageal interventions

Current Opinion in Gastroenterology

Volumn 14, Issue 4, 1998, Pages 350-358

  Binmoeller, Kenneth F ^a   Bohnacker, Sabine ^b   Soehendra, Nib ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN;

ARGON LASER; BIODEGRADATION; CANCER PALLIATIVE THERAPY; DIGESTIVE SYSTEM CANCER; ENDOSCOPIC THERAPY; ESOPHAGUS ACHALASIA; ESOPHAGUS CANCER; ESOPHAGUS DISEASE; ESOPHAGUS DIVERTICULOSIS; ESOPHAGUS FUNCTION; EUROPE; FLUORESCENCE SPECTROSCOPY; FRACTIONATION; HEALTH CARE COST; HUMAN; PHOTODYNAMIC THERAPY; REVIEW; STENT; UNITED STATES; ZENKER DIVERTICULUM;

EID: 0031827003     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199807000-00015     Document Type: Review

References (42)

1. Eckardt VF, Kanzler G, Westermeier T: Complications and their impact •• after pneumatic dilation for achalasia: prospective long-term follow-up study. Gastrointest Endosc 1997, 45:349-353. This study of 67 consecutive patients with achalasia who underwent pneumatic dilatation suggests that complications are underestimated and underreported. since more than 30% of all patients developed either prolonged pain or important morphologic lesions including perforations, hematomas, and diverticula. The perforation rate, however, was very low (1.5%), and as pointed out in an accompanying editorial the clinical significance of the reported complications is questionable.
2. Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN: Botulinum toxin for achalasia; long-term outcome and predictors of response. Gastroenterology 1996, 110:1410-1415.
3. Dufour JF, Fawaz KA, Libby ED: Botulinum toxin injection for secondary achalasia with esophageal varices. Gastrointest Endosc 1997, 45:191-193.
4. Perez-Arroyo H, Hunter J, Waring JP: Botulinum toxin injection for an esophageal muscular A-ring. Gastrointest Endosc 1997, 45:193-195.
5. De Vault KR: Dysphagia from esophageal diverticulosis responding to botulinum toxin injection. Am J Gastroenterol 1997, 92:895-897.
6. Eaker EY, Gordon JM, Vogel SB: Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia. Dig Dis Sci 1997, 42:724-727.
7. Hoffman BJ, Knapple WL, Bhutani MS, Verne GN, Hawes RH: Treatment • of achalasia by injection of botulinum toxin under endoscopic ultrasound guidance. Gastrointest Endosc 1997, 45:77-79. Performed in four patients, there were no complications and patients tolerated a normal diet within 48 to 72 hours of treatment with no recurrence of dysphagia over a median period of 8.8 months. Further studies are needed to determine whether EUS-guided application of the drug into the sphincter muscle improves the results of Botox injection.
8. Wahab PJ, Mulder CJ, Den Hartog G, Thies JE: Argon plasma coagulation •• in flexible gastrointestinal endoscopy: pilot experiences. Endoscopy 1997, 29:176-181. Report of endoscopic APC used to treat various forms of gastrointestinal pathology in 125 patients, including 15 patients with carcinoma of the esophagus and 31 patients with Zenker's diverticulum.
9. Dumoulin FL, Terjung B, Neubrand M, Scheurlen C, Fischer HP. • Sauerbruch T: Treatment of barrett's esophagus by endoscopic argon plasma coagulation. Endoscopy 1997, 29:751-753. Two patients with long segment of Barrett's epithelium without dysplasia were treated by APC. No serious complications occurred, but both patients complained of retrosternal pain and dysphagia after treatment. Barrett's epithelium was replaced by normal squamous epithelium over five to seven sessions. Extensive biopsies after treatment revealed no remnants of metaplastic epithelium.
10. Lightdale CJ, Heier SK, Marcon NE, McCaughan JS, Jr, Gerdes H, Overholt BF, Sivak MV. Jr, Stiegmann GV, Nava HR: Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:Yag laser for palliation of esophageal cancer: A multicenter randomized trial. Gastrointest Endosc 1995, 42:507-512.
11. Sibille A, Lambert R, Souquet JC, Sabben G. Descos F: Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 1995, 108:337-344.
12. Overholt BF, Panjehpour M: Barrett's esophagus: photodynamic therapy for ablation of dysplasia. reduction of specialized mucosa, and treatment of superficial esophageal cancer. Gastrointest Endosc 1995, 42:64-70.
13. Messmann H, Szeimies RM, Bsumler W, Knychel R, Zirngibl H, •• Schslmerich J, Holstege A: Enhanced effectiveness of photodynamic therapy with laser light fragmentation in patients with esophageal cancer. Endoscopy 1997, 29:275-280. laser light fractionation during PDT improved the effectiveness of treatment in a small number of patients, but also increased the occurrence of mild esophageal stenosis. This approach needs further study.
14. Panjehpour M, Overholt BF, Vo-Dinh T, Haggitt RC, Edwards DH. Buckley FP, III: Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology 1996, 111:93-101.
15. Von Holstein CS, Nilsson AM. Andersson-Engels S, Willen R, Walther B, •• Svanberg K: Detection of adenocarcinoma in Barrett's esophagus by means of laser-induced fluorescence. Gut 1996, 39:711-716. Low dose Photofrin was used to detect neoplasia with laser-induced fluorescence in patients with Barrett's metaplastic epithelium and esophageal adenocarcinoma. The highest fluorescence ratios were obtained for adenocarcinoma tissue; metaplastic Barrett's epithelium also yielded higher fluorescence ratios than normal tissue.
16. Soehendra N, Binmoeller KF, Bohnacker S, Seitz U, Brand B. Thonke F, •• Gurakuqi G: Endoscopic snare mucosectomy in the esophagus without any additional equipment: a simple technique for resection of flat early cancer. Endoscopy 1997, 29:380-383. Simplified technique for snare mucosectomy of flat early cancers in the esophagus using only a standard monofilament polypectomy snare. Complete removal of the early cancer was achieved in all cases within a single session without any complications. Tumor recurrence was not observed over a median follow-up of 7 months.
17. Takeshita K, Tani M, lnoue H, Saeki I. Hayashi S, Honda T, Kando F, Saito • N, Endo M: Endoscopic treatment of early oesophageal or gastric cancer. Gut 1997, 40:123-127. Impressive results of endoscopic mucosectomy of early esophageal dysplasia and cancer in 56 patients using an endoscope fitted with a transparent plastic cap attachment.
18. Hyun JH, Jeen YT, Chun HJ, Lee HS, Lee SW, Song CW. Choi JH, Um • SH, Kim CD, Ryu HS: Endoscopic resection of submucosal tumor of the esophagus: results in 62 patients. Endoscopy 1997, 29:165-170. Submucosal tumors with sizes ranging from 6 mm to 7.5 cm in 62 patients were removed endoscopically. The results are impressive, but it is questionable whether asymptomatic patients with small submucosal tumors need to undergo resection of these tumors.
19. Saeed ZA, Ramirez FC, Hepps KS, Cole RA, Schneider FE, Ferro PS, •• Graham DY: An objective end point for dilation improves outcome of peptic esophageal strictures: a prospective randomized trial. Gastrointest Endosc 1997, 45:354-359. An objective endpoint for dilation of esophageal strictures was found to reduce stricture recurrence and the need for subsequent dilation. Furthermore, the initial subjective improvement of dysphagia did not predict long-term success. Still, it may be difficult to convince patients to undergo rebougienage without dysphagia.
20. Mutaf O: Treatment of corrosive esophageal strictures by long-term stenting. J Pediatr Surg 1996, 31:681-685.
21. Song HY, Park SI, Do YS, Yoon HK, Sung KB, Sohn KH, Min YI: • Expandable metallic stent placement in patients with benign esophageal stricture. Radiology 1997, 201:131-136. A variety of self-expandable metal stents were used to treat benign esophageal strictures in 12 patients. Late complications occurred in all patients, and two required a second stent.
22. Bhutani MS, Usman N, Shenoy V, Qarqash A, Singh A, Barde CJ, Gopalswamy N: Endoscopic ultrasound miniprobe-guided steroid injection for treatment of refractory esophageal strictures. Endoscopy 1997, 29:757-759.
23. Ell C, May A: Self-expanding metal stents for palliation of stenosing tumors • of the esophagus and cardia: a critical review. Endoscopy 1997, 29:392-398. In-depth review of the published literature on SEMS.
24. Ramirez FC, Dennert B, Zierer ST, Sanowski RA: Esophageal self-expand• able metallic stents-indications, practice, techniques and complications: results of a national survey. Gastrointest Endosc 1997, 45:360-364. Only 46% of the SEMS users considered SEMS to be the first line of therapy for inoperable malignant dysphagia. There was a 15% rate of technical failures such as incomplete expansion and misplacement.
25. Dougents D, Petsas T, Bouboulis N, Leukaditou C, Vagenas C, Kardamakis D, Kalfarentzos F: Management of non-resectable malignant esophageal stricture and fistula. Eur J Cardiothorac Surg 1997, 11:38-45.
26. Segalin A, Bonavina L, Carrazone A, Ceriani C, Peracchia A: Improving results of esophageal stenting: a study on 160 consecutive unselected patients. Endoscopy 1997, 29:701-709.
27. Dorta G, Binek J, Blum AL, Bühler H, Felley CP, Koelz HR, et al.: Comparison between esophageal wallstent and ultraflex stents in the treatment of malignant stenoses of the esophagus and cardia. Endoscopy 1997, 29:149-154. Wallstents were found to have several significant short-and long-term advantages over the Ultraflex stents, including better relief of dysphagia and fewer reinterventions. The major complication of Wallstents was tumor ingrowth, while that of Ultraflex stents was incomplete deployment.
28. Schmassmann A, Meyenberger C, Knuchel J, Binek J, Lammer F. Kleiner • B. et al.: Self-expanding metal stents in malignant esophageal obstruction: A comparison between two stent types. Am J Gastroenterol 1997, 92(3):400-06. Wallstents had an early complication rate of 32% and procedure-related mortality of 16%, which was significantly higher than that in the Ultraflex group. However, Wallstents had significantly lower rates of stent dysfunction and required fewer reinterventions.
29. Nelson DB, Axelrad AM, Fleischer DE, Kozarek RA, Silvis SE, Freeman ML. Benjamin SB: Silicone covered wallstent prototypes for palliation of malignant esophageal obstruction and digestive-respiratory fistulas. Gastrointest Endosc 1997. 45:31-37.
30. Saxon RR, Morrison KE, Lakin PC, Petersen BD, Barton RE, Katon RM, Keller FS: Malignant esophageal obstruction and esophagorespiratory fistula: Palliation with a polyethylene-covered Z-stent. Radiology 1997, 202:349-354.
31. Bethge N, Sommer A, Vakil N: A prospective trial of self-expanding metal • stents in the palliation of malignant esophageal strictures near the upper esophageal sphincter. Gastrointest Endosc 1997, 45:300-303. SEMS intended for eight patients with malignant stenosis located within 3 cm of the upper esophageal sphincter were tolerated well in five of six patients in whom placement was successful.
32. Henne TH, Schaeff B, Paolucci V: Small bowel obstruction and perforation. A rare complication of an esophageal stent. Surg Endosc 1997, 11:383-384.
33. Siersema PD, Tan TG, Sutorius FFJM, Dees J, Van Blankenstein M: Massive hemorrhage caused by a perforating gianturco Z-stent resulting in an aortoesophageal fistula. Endoscopy 1997, 29:416-420.
34. May A, Fee G, Bauer R, EII C: Mucosal strangulation due to self-expanding coil stents. Gastrointest Endosc 1997, 46:273-276.
35. Dennert B. Ramirez FC, Sanowski RA: Pericardioesophageal fistula associated with metallic stent placement. Gastrointest Endosc 1997, 45:82-84.
36. Adam A, Ellul J, Watkinson AF, Tan BS, Morgan RA, Saunders MP, Mason • RC: Palliation of inoperable esophageal carcinoma: a prospective randomized trial of laser therapy and stent placement. Radiology 1997, 202:344-348. Sixty patients with inoperable esophageal carcinomas and dysphagia to endoscopic dilation (45F) followed by laser treatment or SEMS placement. Dysphagia score improvement was better in the stented group. All patients in the laser group required reinterventions, but surprisingly a large number of stented patients also required reinterventions, signifying that there is much work to be done to improve the results of stenting.
37. Scheider DM, Siemens M, Cirocco M, Haber GB, Kandel G, Kortan P, Marcon NE: Photodynamic therapy for the treatment of tumor ingrowth in expandable esophageal stents. Endoscopy 1997, 29:271-274.
38. Fry SW, Fleischer DE: Management of a refractory benign esophageal • stricture with a new biodegradable stent. Gastrointest Endosc 1997, 45:179-182. A biodegradable self-expanding prototype Esophagocoil stent made of poly-L-lactide was successfully placed and initially relieved dysphagia, but later fractured and obstructed the esophageal lumen. More work on a good idea required.
39. Song HY, Park SI, Jung HY, Kim SB, Kim JH, Huh SJ, Kim YK, Park S, • Yoon HK, Sung KB, Min YI: Benign and malignant esophageal strictures: Treatment with a polyurethane-covered retrievable expandable metallic stent. Radiology 1997, 203:747-752. By pulling at a loop with a specially designed hook, the proximal segment of a polyurethane-covered Z-stent can be compressed and extracted into an overtube.
40. Haringsma J, Ferwerda J, Dekker W. Brom HLF: Preliminary experience • with a new ultraviolet-cured expandable plastic endoprosthesis in the management of malignant esophageal strictures. Endoscopy 1997, 29:188-191. The new plastic stent consisted of two polyethylene layers with an acrylate-based resin between them. For placement, the stent was compressed and mounted coaxially over a 7.5 mm over-the-wire balloon catheter. The stent was inflated to a maximum diameter of 62 F.
41. Bisgaard T, Wødeman J, Heindorff H, Svendsen LB: Nonsurgical treatment of esophageal perforations after endoscopic palliation in advanced esophageal cancer. Endoscopy 1997, 29:155-159.
42. Adamek HE, Jakobs R, Dorlars D, Martin WR, Kršmer MU, Riemann J F: Management of esophageal perforations after therapeutic upper gastrointestinal endoscopy. Scand J Gastroenterol 1997, 32:411-414.